Regorafenib Dose Optimization Study (ReDOS): A Phase II Randomized Study of Lower Dose Regorafenib Compared to Standard Dose Regorafenib in Patients with Refractory Metastatic Colorectal Cancer (mCRC)

Lower or Standard Dose Regorafenib in Treating Patients With Refractory Metastatic Colorectal Cancer »